Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Br J Cancer ; 111(11): 2142-51, 2014 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-25268374

RESUMEN

BACKGROUND: Optimal expression and proper function of key mitotic proteins facilitate control and repair processes that aim to prevent loss or gain of chromosomes, a hallmark of cancer. Altered expression of small regulatory microRNAs is associated with tumourigenesis and metastasis but the impact on mitotic signalling has remained unclear. METHODS: Cell-based high-throughput screen identified miR-378a-5p as a mitosis perturbing microRNA. Transient transfections, immunofluorescence, western blotting, time-lapse microscopy, FISH and reporter assays were used to characterise the mitotic anomalies by excess miR-378a-5p. Analysis of microRNA profiles in breast tumours was performed. RESULTS: Overexpression of miR-378a-5p induced numerical chromosome changes in cells and abrogated taxol-induced mitotic block via premature inactivation of the spindle assembly checkpoint. Moreover, excess miR-378a-5p triggered receptor tyrosine kinase-MAP kinase pathway signalling, and was associated with suppression of Aurora B kinase. In breast cancer in vivo, we found that high miR-378a-5p levels correlate with the most aggressive, poorly differentiated forms of cancer. INTERPRETATION: Downregulation of Aurora B by excess miR-378a-5p can explain the observed microtubule drug resistance and increased chromosomal imbalance in the microRNA-overexpressing cells. The results suggest that breast tumours may deploy high miR-378a-5p levels to gain growth advantage and antagonise taxane therapy.


Asunto(s)
Neoplasias de la Mama/patología , MicroARNs/fisiología , Mitosis , Aurora Quinasa B/antagonistas & inhibidores , Neoplasias de la Mama/química , Neoplasias de la Mama/genética , Proteínas Portadoras/fisiología , Proliferación Celular , Segregación Cromosómica , Quinasas MAP Reguladas por Señal Extracelular/antagonistas & inhibidores , Femenino , Células HeLa , Humanos , Sistema de Señalización de MAP Quinasas/fisiología , Clasificación del Tumor , Proteínas de Unión al ARN , Receptores de Estrógenos/análisis , Factor A de Crecimiento Endotelial Vascular/biosíntesis
2.
Br J Cancer ; 108(1): 82-90, 2013 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-23321512

RESUMEN

BACKGROUND: Epothilones are a novel group of microtubule (mt) targeting cancer drugs that bind to the ß-subunit of the αß-tubulin dimer. Epothilones inhibit cell proliferation and induce cell death by interfering with the normal mt function. In this study, we examined the consequences of altered expression of human ß-tubulin isotypes in terms of the epothilone drug response in human lung and breast cancer cell lines. METHODS: The ß-tubulin isotypes TUBB2A-C, TUBB3 and TUBB were silenced or overexpressed in A549, A549EpoB40 and MCF7 cell lines in the presence or absence of epothilones. The drug effects on cell proliferation, mitosis and mt dynamics were determined using live cell microscopy and immunofluorescence assays. RESULTS: Loss of TUBB3 enhanced the action of epothilones. TUBB3 knockdown increased the severity of drug-induced mitotic defects and resulted in stabilisation of the mt dynamics in cells. Moreover, exogenous expression of TUBB3 in the epothilone resistant cell line conferred the response to drug treatments. In contrast, reduced levels of TUBB2A-C or TUBB had not apparent effect on the cells' response to epothilones. CONCLUSION: Our results show that the expression of TUBB3 contributes to the cellular response to epothilones, putatively by having an impact on the mt dynamics.


Asunto(s)
Antineoplásicos/farmacología , Epotilonas/farmacología , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/metabolismo , Mitosis/efectos de los fármacos , Tubulina (Proteína)/metabolismo , Línea Celular Tumoral , Femenino , Silenciador del Gen , Humanos , Células MCF-7 , Neoplasias , Huso Acromático/efectos de los fármacos , Transfección , Tubulina (Proteína)/genética , Moduladores de Tubulina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA